Navigation Links
Varian Medical Systems Receives FDA 510(k) Clearance for Use of Transponder to Monitor Motion During Radiotherapy Anywhere in Body
Date:2/28/2012

PALO ALTO, Calif., Feb. 28, 2012 /PRNewswire/ -- Varian Medical Systems (NYSE: VAR) has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for a surface beacon transponder to be used with the Varian Calypso system as a real-time tracking device capable of monitoring motion during radiotherapy treatments for indications anywhere in the body. The Surface Beacon® Transponder is placed temporarily on the skin for real time tracking of respiratory and other patient motion during radiotherapy, thereby greatly expanding the number of cancer sites for which the Calypso technology can be used.  

"Our new surface transponder allows users to track patient motion in real-time during treatment," says Chris Toth, vice president of marketing for Varian's Oncology Systems group. "It can be placed on a patient's chest wall to monitor respiratory motion during radiotherapy. It is designed to improve targeting in some of the most prevalent types of cancer, including breast cancer."

For example, chest wall monitoring during treatment of the left breast can correlate with the position of the heart. Having a tool to monitor this position in real-time enables clinicians to design treatments that eliminate or significantly reduce dose to the heart. Breast cancer is the most common cancer for women in the U.S. – an estimated 30 percent* of women will develop breast cancer over their lifetime.

Varian acquired Calypso in October 2011 to extend the company's range of real-time tracking tools aimed at enhancing the precision of radiotherapy treatments.

"These products are a perfect complement for Varian's motion management technology, including our TrueBeam™ platform and dynamic imaging tools for highly focused radiosurgery," says Tim Guertin, president and CEO of Varian Medical Systems. "Achieving 510(k) clearance for the Surface Beacon Transponder expands the range of applications for the Calypso 'GPS for the body' real-time tracking solution."

*American Cancer Society 2011

Editorial contact: Neil Madle, Varian Medical Systems, +44 7786 526068

About Varian Medical Systems
Varian Medical Systems, Inc., of Palo Alto, California, is the world's leading manufacturer of medical devices and software for treating cancer and other medical conditions with radiotherapy, radiosurgery, and brachytherapy. The company supplies informatics software for managing comprehensive cancer clinics, radiotherapy centers and medical oncology practices. Varian is a premier supplier of tubes and digital detectors for X-ray imaging in medical, scientific, and industrial applications and also supplies high-energy X-ray devices for cargo screening and non-destructive testing applications. Varian Medical Systems employs approximately 5,900 people who are located at manufacturing sites in North America, Europe, and China and approximately 70 sales and support offices around the world. For more information, visit http://www.varian.com or follow us on Twitter.

 


'/>"/>
SOURCE Varian Medical Systems
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. First Patient Enrolled in Europe in Ovature Phase III Ovarian Cancer Trial
2. Sunesis Pharmaceuticals Reports Preliminary SNS-595 Activity in Ovarian Cancer Clinical Trial at AACR-NCI-EORTC International Conference
3. Clinical Studies of OvaRex in Advanced Ovarian Cancer Fail to Meet Primary Endpoint
4. Northwest Biotherapeutics Conducting Ovarian Cancer Clinical Trial With DCVax(R)-L at University of Pennsylvania
5. EntreMed Commences Phase 2 Study With MKC-1 in Ovarian/Endometrial Cancers
6. BioNumerik Commences Global Phase III Ovarian Cancer Trial on Novel Anticancer Drug Candidate Known as Karenitecin(R)
7. Sunesis Pharmaceuticals Reports Positive Interim Data for SNS-595 Single-Agent Activity in Platinum-Resistant Ovarian Cancer
8. Vermillions Biomarkers Prove Beneficial in Identifying Women With Ovarian Cancer and Detecting Early-Stage Disease
9. BSI-201 Demonstrates Significant Tumor Growth Inhibition and Increased Survival Rates in Preclinical Ovarian Cancer Studies
10. BiPar Sciences Expands Phase 2 Clinical Trials of BSI-201, a Novel DNA Repair Inhibitor, in Ovarian Cancer
11. Join NPRs David Ewing Duncan, Author Jessica Queller and a Panel of Medical and Legal Experts in a 90-Minute Webcast on Genetic Testing, Genomic Medicine and Breast & Ovarian Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2016)... Allergan plc (NYSE: AGN ), a ... previously announced Accelerated Share Repurchase (ASR) Program. Logo - ... ... previously announced, the Company entered into a variable tenor ASR ... repurchase $10 billion of its ordinary shares. Approximately 40.5 million ...
(Date:11/30/2016)... 2016 Research and Markets has ... Neuromodulation, Neurovascular, Neurosurgical and Monitoring Devices 2017 - MedView" ... ... The full report suite on the U.S. market for neurological ... intracranial pressure monitoring devices, detachable coils, liquid embolics, catheters, guidewires, ...
(Date:11/30/2016)... 2016 Varian Medical Systems (NYSE: ... JUST Company in the Healthcare Equipment and Services industry, ... inaugural "JUST 100 List." The rankings are based on ... conducted on attitudes towards corporate behavior, involving 50,000 Americans ... U.S companies against their peers within 32 major industries. ...
Breaking Medicine Technology:
(Date:12/2/2016)... , ... December 02, 2016 , ... ... veterinarian diagnostic imaging systems and the first company to offer robotic imaging ... Heart at their tradeshow booth # 941 for the American Association of Equine ...
(Date:12/2/2016)... ... 2016 , ... Rijuven Corp launches rejiva ( http://www.rejiva.com ), a unique wearable ... wearable health technology on the market can deliver all that rejiva can. , “Rejiva ... about their health than the usual heart rate and steps taken”, adds Evens Augustin, ...
(Date:12/2/2016)... ... December 02, 2016 , ... "Pro3rd Accents Volume 2 is a ... versatile lower third titles with just a few clicks of the mouse," said Christina ... 30 lower third animations. Choose from various styles with accented animations, rigid boxes, simplistic ...
(Date:12/2/2016)... (PRWEB) , ... December 02, 2016 , ... ... hot meals to needy individuals and families from eight different sites throughout Miami-Dade ... Thanksgiving Day. Over 1,000 volunteers worked very hard on Thanksgiving morning by putting ...
(Date:12/2/2016)... (PRWEB) , ... December 02, 2016 , ... ... Technologist/Clinical Laboratory Scientist & Author of Type 2 Diabetes: The Owner’s Manual, ... The Sharon Kleyne Hour Power of Water, Global Climate Change and Your Health ...
Breaking Medicine News(10 mins):